Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma
| Autor: | Eva-B. Bröcker, A Schwaaf, T Moll, W. Dummer, Jürgen C. Becker, Martin Leverkus |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Cancer Research Skin Neoplasms medicine.medical_treatment Cell Enzyme-Linked Immunosorbent Assay Dermatology Disease Malignant transformation Elevated serum In vivo medicine Humans Melanoma Aged Aged 80 and over business.industry Middle Aged medicine.disease Interleukin-10 Interleukin 10 medicine.anatomical_structure Cytokine Oncology Case-Control Studies Lymphatic Metastasis Cancer research Female business |
| Zdroj: | Melanoma Research. 5:67-68 |
| ISSN: | 0960-8931 |
| Popis: | Interleukin-10 (IL-10), originally described as a product of TH2 cell clones, has been recognized as a potential immunosuppressive cytokine. To investigate the relevance of IL-10 in melanoma patients in vivo, we studied IL-10 serum levels in 104 untreated patients in different stages of the disease; 20 healthy subjects and 22 patients with inflammatory dermatoses served as controls. Serum levels were measured by ELISA. Only one of 31 patients with stage I melanoma (3%) and one of 16 stage II patients (6%) showed detectable IL-10 levels. Interestingly, six of 17 patients with lymph node metastases (stage III, 35%) and 29 of 40 patients with widespread disease (stage IV, 73%) revealed IL-10 levels of 15-480 pg/ml. No healthy person and only one control patient had a detectable IL-10 serum level. The data suggest that IL-10 in melanoma patients may contribute to down-modulation of anti-tumour responses in vivo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|